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Formaldehyde is a well-known airborne
contaminant causing eye, nose, and throat
irritation as well as airway irritation and slight
neuropsychologic changes (Hester and
Harrison 1998; Samet et al. 1988). 
The major indoor sources of formalde-
hyde are off-gassing from urea–formaldehyde
foam insulation, particle board, paneling, ply-
wood, some carpets and furniture, and, to a
lesser extent, tobacco smoke and indoor com-
bustion sources. Indoor concentrations of
formaldehyde can vary between different
countries (Sakaï et al. 2004). In a Japanese
study, formaldehyde concentrations ranged
between 91.25 and 290 μg/m3 (Minami et al.
2002), whereas in the United Kingdom, the
highest level measured in 876 homes was
much lower (median = 24 μg/m3) (Brown
et al. 2002). Indoor formaldehyde concentra-
tions measured in mobile homes in the
United States ranged from nondetectable
values to 575 μg/m3 (Liu et al. 1991). 
Indoor concentrations generally exceed
those outdoors, and studies on formaldehyde
levels in homes have demonstrated higher
formaldehyde concentrations in newer
compared with older dwellings, with higher
levels in buildings built after 1970 (Gilbert
et al. 2005).
Formaldehyde is an etiologic factor in
occupational asthma. However, although
formaldehyde may cause asthma in some
individuals, this occurs relatively rarely
(Nordman et al. 1985; Paustenbach et al.
1997). 
Whether nonoccupational exposure to
formaldehyde is related to asthma is still sub-
ject to discussion (Delﬁno 2002; Institute of
Medicine 2000). In murine models, formalde-
hyde exposure has been shown to enhance the
allergic eosinophilic airway inflammation in
sensitized mice (Sadakane et al. 2002). In a
part of the European Community Respiratory
Health Survey, asthma prevalence was greater
for newly painted homes, consistent with
greater differences in formaldehyde exposure
(Wieslander et al. 1997). A relationship
between physician-diagnosed asthma and
indoor concentration of formaldehyde was
reported even at low levels of exposure in chil-
dren (Rumchev et al. 2002). Franklin et al.
(2000) reported that exposure to formaldehyde
in homes could produce a subclinical inﬂam-
matory response in the airways of healthy chil-
dren. A possible association between exposure
to formaldehyde and allergic sensitization to
common aeroallergens has been suggested by
another cross-sectional study in children
(Garrett et al. 1999). 
Human exposure studies can provide valu-
able data for assessing more specifically the
acute effects of air pollutants, particularly the
airway response to allergen (Sandström 1995).
The hypothesis that formaldehyde enhances
asthmatic response to allergen has not yet
been investigated in controlled conditions in
humans. To test this hypothesis, we carried
out this controlled human study to investigate
the effect of a short exposure to 500 μg/m3
formaldehyde on asthmatic response to
inhaled allergen.
Methods 
Subjects. Twelve subjects (seven men and ﬁve
women) participated in the study (Table 1).
All of the subjects were between 18 and
44 years of age (median = 25 years) and had
been diagnosed with intermittent asthma and
allergy to pollen. 
The diagnosis of intermittent asthma was
based on reversible attacks of dyspnea less than
twice per week and attacks of night respiratory
problems, with a peak expiratory ﬂow (PEF)
> 80% of predicted value and/or normal 
pulmonary function test, less than twice per
month. All subjects were allergic to grass
pollen, as determined by history of seasonal
asthma symptoms and allergy skin testing. All
subjects used inhaled β2-agonist as needed,
and nine used antihistamine (anti-H1) medi-
cations during the pollen season. None were
receiving anti-inﬂammatory therapy or other
current treatments. The study was performed
outside the grass pollen season. All subjects
were nonsmokers. 
Before the the exposure experiments
began, each subject underwent a physical
examination. Also, seasonal allergy to grass
pollen was confirmed by positive skin prick
test performed using a standardized extract
including ﬁve grass pollen allergens: Dactylis
glomerata, Anthoxanthum odoratum, Lolium
perenne, Poa pratensis, and Phleum pratense
(Phl p5) (Stallergenes Laboratory, Antony,
France). Skin prick test responses for allergens
were considered positive if the wheal diameter
Address correspondence to V. Ezratty, Service des
Etudes Médicales d’EDF et de Gaz de France,
22-28 rue Joubert, 75009 Paris, France. Telephone:
33 1 55 31 46 04. Fax: 33 1 55 31 46 20. E-mail:
veronique.ezratty@edfgdf.fr
We thank M. Grandsaigne and V. Leçon-Malas
for their contribution to this work, and S. Billot
Bonef and D. Ormandy for their valuable advice.
This work was supported by Electricité de France
as part of a research programme on Indoor Air
Quality.
The authors declare they have no competing
ﬁnancial interests.
Received 13 June 2006; accepted 7 November 2006.
Effect of Formaldehyde on Asthmatic Response to Inhaled Allergen Challenge 
Véronique Ezratty,1 Marcel Bonay,2,3 Catherine Neukirch,2,4,5 Gaëlle Orset-Guillossou,1 Monique Dehoux,2,6
Serge Koscielny,7 Pierre-André Cabanes,1 Jacques Lambrozo,1 and Michel Aubier2,3,4,5
1Service des Etudes Médicales d’EDF et de Gaz de France, Paris, France; 2Unité 700, INSERM, Faculté Xavier Bichat, Paris, France;
3Service de Physiologie-Explorations Fonctionnelles, 4Service de Pneumologie, 5Clinical Centre of Investigation INSERM 007, and
6Biochimie A, Hôpital Bichat-Claude Bernard, Paris, France; 7Department of Biostatistics, Institut Gustave Roussy, Villejuif, France
BACKGROUND: Exposure to formaldehyde may lead to exacerbation of asthma.
OBJECTIVES: Our aim in this study was to investigate whether exposure to a low level (500 µg/m3)
of formaldehyde enhances inhaled allergen responses. 
METHODS: Twelve subjects with intermittent asthma and allergy to pollen were exposed, at rest, in
a double-blind crossover study to either formaldehyde or purified air for 60 min. The order of
exposure to formaldehyde and air-only was randomized, and exposures were separated by 2 weeks.
We also performed an allergen inhalation challenge after each exposure. Airway responsiveness to
methacholine and lower airway inﬂammation (induced sputum) were assessed 8 hr after allergen
challenge. 
RESULTS: The median dose of allergen producing a 15% decrease in forced expiratory volume in
1 sec (PD15FEV1) was 0.80 IR (index of reactivity) after formaldehyde exposure compared with
0.25 IR after air-only exposure (p = 0.06). Formaldehyde exposure did not affect allergen-induced
increase in responsiveness to methacholine (p = 0.42). We found no formaldehyde-associated effect
on the airway inflammatory response, in particular the eosinophilic inflammatory response,
induced by the allergen challenge 8 hr before. 
CONCLUSION: In this study, exposure to 500 µg/m3 formaldehyde had no signiﬁcant deleterious
effect on airway allergen responsiveness of patients with intermittent asthma; we found a trend
toward a protective effect.
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2006]was at least 3 mm greater than that for the
negative control and at least 50% of the diame-
ter of the positive control. Blood samples were
obtained for analysis of total IgE and
eosinophils in serum. Pulmonary function tests
were performed and sputum was collected. All
subjects were free from upper respiratory infec-
tions for at least 4 weeks before the study.
Before enrollment in the study, all participants
gave written informed consent. The study was
approved by the ethical committee of Saint-
Germain-en-Laye-Hospital (project 00019,
registered on 9 May 2000).
Study protocol. In a crossover design study,
each subject was exposed at rest to ﬁltered air
or to a concentration of 500 μg/m3 (0.4 ppm)
formaldehyde for 60 min on two separate days.
The exposures were performed at the same
hour (0700 hours) and occurred on the same
day of the week, with an interval of 2 weeks
between exposure. The order of exposure to
formaldehyde and air-only was double-blinded
and randomized. The only member of the
research team aware of the type of exposure
was the engineer in charge of the injection of
formaldehyde into the chamber. The nature of
exposure was made known to the other mem-
bers of the team only after completion of the
statistical analysis. 
Lung function was measured with a
spirometer according to the European
Community Respiratory Health Survey speci-
ﬁcations; measurements were taken immedi-
ately before, during, and 8 hr after the end of
the allergen challenge. Forced expiratory vol-
ume in 1 sec (FEV1) and PEF were measured
with a portable combined spirometer every
15 min during the exposure to formaldehyde
or air-only in the chamber and every hour
until the methacholine provocation test,
which was performed 8 hr after the end of the
allergen bronchial challenge.
Formaldehyde/clean air exposure. A
8.8-m3 exposure chamber was installed at the
Hospital Bichat in Paris. The chamber was
supplied with fresh, particle-free air at a mean
temperature of 25°C and a mean relative
humidity of 32%. The air supply passed
through both HEPA and activated carbon ﬁl-
ters. The formaldehyde atmosphere was cre-
ated by injecting and diluting saturated vapors
from a heated solution of formaldehyde at the
exit of the ﬁltration box; these vapors ﬂowed
into the ventilation diffuser located in the cen-
ter of the chamber ceiling. A continuous 1-hr
injection of the formaldehyde solution was suf-
ﬁcient to reach a steady state. The formalde-
hyde concentration in the chamber was
monitored continuously with semiconductor
gas sensor technology during the experiments
to ensure that there was no fluctuation in
formaldehyde levels during exposure. The air
ejected from the chamber was evacuated out-
side the building without recirculation. 
Allergen bronchial challenge. Each expo-
sure to formaldehyde or air-only was immedi-
ately followed by an allergen inhalation
challenge. This challenge involved an auto-
matic inhalation-synchronized Mefar MB3
dosimeter jet nebulizer (Mefar SpA, Bovezzo,
Italy). We used the same standardized extract
of ﬁve grass pollen allergens as for the skin test
(Stallergenes Laboratory) The initial allergen
concentration of standardized pollen extract
was 0.1 or 0.2 IR (index of reactivity), as pre-
viously described by Aubier et al. (1998). The
concentration of inhaled allergen was doubled
every 15 min; the FEV1 was measured imme-
diately after each doubling and again 10 min
after each inhalation. The dose of allergen pro-
ducing a 15% decrease in the FEV1 was
defined as the PD15FEV1. If the FEV1 had
fallen by ≥ 10%, we required that it be mea-
sured again every 5 min until no further
decrease was observed. Once it reached that
point, inhalation of a higher concentration
could continue. No further allergen was given
a) when FEV1 had fallen by ≥ 15%; b) when
the highest dose of 2 IR was reached (in that
case PD15FEV1 was considered equal to 2 IR);
or c) if respiratory symptoms occurred.
Graphical representations of FEV1 and PEF
according to time were performed during the
8 hr following allergen bronchial challenge for
each of the 24 exposures. PD15FEV1 was esti-
mated without knowing which arm was the
treatment arm.
Pulmonary function and methacholine-
challenge testing. We measured responsiveness
to methacholine 8 hr after the allergen
bronchial challenge ended. All tests were per-
formed with the same dosimeter used for aller-
gen inhalation. The nebulizers were changed
after each test. Flow-volume curves were
obtained with a Biomedin spirometer
(Biomedin Srl, Padova, Italy) in order to
determine FEV1, forced vital capacity (FVC),
forced expiratory ﬂow between 25% and 75%
of the vital capacity, and PEF. The spirometry
technique met international standards, and
references values were those of the European
Respiratory Society (Quanjer et al. 1993).
Results are given as percentages of predicted
values. We assessed airway responsiveness by
methacholine challenge testing using an auto-
matic inhalation-synchronized Mefar MB3
dosimeter jet nebulizer (Mefar SpA., Bovezzo,
Italy) as previously described by Aubier et al.
(1992). After inhalation of isotonic saline as a
control, subjects were administered metha-
choline until the FEV1 had dropped by ≥ 20%
from the post-saline value, or until the maxi-
mum cumulative dose of 4 mg had been given.
The cumulative doses administered were
0.0156, 0.0625, 0.25, 1.0, 2.0, and 4.0 mg. A
3-min interval was allowed before each dose
increment. FEV1 was measured 1 min after
each dose; we used the best of three acceptable
measurements to create dose–response curves.
The methacholine provocative dose (PD) caus-
ing a 20% decrease in FEV1 from control
FEV1 (PD20 methacholine) was determined by
interpolation from the dose–esponse curve
(Chai et al. 1975).
Sputum induction and measurement of
inﬂammatory markers. Sputum induction was
performed at baseline and immediately after
the methacholine challenge with an aerosol of
hypertonic saline, following the method of Pin
et al. (1992). At the beginning of the test and
before each period of inhalation, FEV1 was
measured for safety. The aerosol was generated
by a Syst’am ultrasonic nebulizer (System
Assistance Medical, Villeneuve sur Lot, France)
with increasing concentrations of saline (3, 4,
and 5%) inhaled via a mouthpiece for 5-min
periods for up to 30 min. Patients were then
asked to rinse their mouth, blow their nose,
and cough sputum into a sterile container. 
The sputum was examined within 1 hr
using a modified method described by
Pizzichini et al. (1996). The entire sputum
sample was poured into a Petri dish and
inspected for salivary contamination under an
inverted microscope; all portions that
appeared free of salivary contamination were
placed in a preweighed 15 mL polystyrene
tube using forceps. Dithiothreitol (0.1%;
Sigma, St. Quentin Fallavier, France) was
freshly diluted in distilled water equal to
4 times the sputum weight and added to the
sputum sample. The mixture was vortexed for
30 sec and placed on a bench rocker and
rocked for 15 min. A further 4 volumes of
Dulbecco’s phosphate-buffered saline was
added to stop the effect of dithiothreitol and
rocked for 5 min. The suspension was ﬁltered
through a 70-μm cell strainer. The resulting
suspension was centrifuged at 800 × g for
10 min, and the supernatant was aspired and
stored in Eppendorf tubes at –70°C in the
presence of aprotinin. 
Total nonsquamous cell counts were per-
formed in a hemocytometer and expressed as
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Table 1. Characteristics of subjects.
Asthma FEV1 at 
Age duration inclusion
Subject (years) Sex (year) Smoking (% pred)
1 34 M 18 N 100
2 33 F 19 N 101
3 45 M 10 N 109
4 18 M 12 N 105
5 24 M 8 N 103
6 28 F 10 E 111
72 6 F 2 0 N 9 5
8 37 F 15 N 109
9 25 M 20 N 101
10 26 F 18 N 93
11 21 M 6 N 108
12 26 M 14 N 89
Abbreviations: E, ex-smoker; F, female; M, male; N, never
smoker; % pred, percent predicted.millions per milligram of selected induced
sputum. The proportion of salivary squamous
cells was noted, and cell viability was deter-
mined using the trypan blue exclusion
method. From the remainder of the filtrate,
10 cytospins were prepared, air-dried, and
ﬁxed. Differential cell counts were performed
by counting 400 cells on May Grünwald
Giemsa–stained slides. Results were expressed
as a percentage of the total nonsquamous
count. Slides were coded, and cell counts
were performed by an expert observer who
did not know the clinical characteristics of the
patients. Only samples with cell viability
> 70% and squamous cell contamination
< 20% were considered adequate.
We measured sputum supernatant con-
centrations of interleukins (IL-1, IL-4, IL-5,
IL-8, IL-10), granulocyte–macrophage
colony-stimulating factor (GM-CSF), mono-
cyte chemotactic protein-1 (MCP-1), tumor
necrosis factor-α (TNF-α), interferon-γ
(IFN-γ), and eotaxin-1 using commercially
available ELISAs (R&D Systems, Abingdon,
UK) according to the manufacturer’s instruc-
tions. The lower detection limits of the assays
were as follows: IL-1, 0.1 pg/mL; IL-4,
0.13 pg/mL; IL-5, 3 pg/mL; IL-8, 10 pg/mL;
IL-10, 0.5 pg/mL; GM-CSF, 0.25 pg/mL;
MCP-1, 5 pg/mL; TNF-α, 0.12 pg /mL;
IFN-γ, 8 pg/mL; and eotaxin-1, 5 pg/mL.
Eosinophil cationic protein levels (ECP)
were measured by a commercially available
enzyme assay (CAP-FEIA, Pharmacia,
St. Quentin-en-Yvelines, France), with a
lower detection limit of 2 ng/mL.
Questionnaire and postexposure follow-up.
After 0, 15, 30, 45, and 60 min of exposure to
formaldehyde or air-only in the chamber, the
subjects were asked 14 questions concerning
respiratory symptoms and perception of dis-
comfort (i.e., perception of an odor, eye irrita-
tion, nose/throat irritation, chest discomfort/
tightness, coughing, shortness of breath, 
nausea, dyspnea, headache, fatigue, dizziness,
other discomfort).
Subjective symptoms and medication
were also recorded. Each subject measured
FEV1 and PEF twice daily with a portable
combined spirometer during the 2-week
interval after each exposure. 
Statistical analysis. We analyzed differences
between two exposures (either between expo-
sures with formaldehyde and air, or between
the ﬁrst exposure and the second exposure after
the washout) using the Wilcoxon’s non-
parametric sign rank test. p-Values < 0.05 were
considered signiﬁcant.
Results
All 12 subjects completed the two exposures
and all of the allergen and methacholine chal-
lenges. Four subjects reported minor com-
plaints during exposure to both air-only and
formaldehyde. One reported nose irritation
during air-only exposure, and another subject
reported having a runny nose during formalde-
hyde exposure but no symptoms or discomfort
during air exposure. No distinct odor was
reported by any subject during exposure to air-
only or formaldehyde. No major clinical
adverse reaction was observed. 
Exposure of allergic asthmatic patients at
rest to 500 μg/m3 formaldehyde for 1 hr had no
direct effect on respiratory function either dur-
ing or immediately after the exposure session.
The FVC and FEV1 values, measured imme-
diately after formaldehyde exposure, were not
significantly different from those obtained
after air-only exposure. 
Allergen bronchial challenge. Airway
responsiveness to allergen was measured using
the PD15FEV1. Formaldehyde versus air-only
exposure resulted in a PD15FEV1 that was
higher in ﬁve patients and unchanged in seven
(Figure 1). The median PD15FEV1 was 0.80
(range, 0.15–2.0) IR after formaldehyde expo-
sure compared with 0.25 (range, 0.1–2.0) IR
after air-only exposure (p = 0.06) (Table 2).
We observed no “order effect” concerning
PD15FEV1: results were not signiﬁcantly dif-
ferent between the ﬁrst exposure to formalde-
hyde or air-only (no wash-out) and the second
exposure (after a wash-out).
Methacholine bronchial challenge.
Methacholine responsiveness was assessed
8 hr after the end of the allergen challenge.
Formaldehyde versus air-only exposure
resulted in a PD20 methacholine that was
lower in three subjects, higher in four, and
unchanged (within a doubling dose) in five
(Figure 1). Formaldehyde exposure did not
affect the allergen-induced increase in respon-
siveness to methacholine (median PD20,
0.17 mg after formaldehyde vs. 0.23 mg after
air-only exposure; p = 0.42) (Table 2). No
“order effect” was observed.
Sputum sample analysis. Eosinophils, ECP,
and MCP-1 increased signiﬁcantly in induced
sputum 8 hr after the allergen challenge com-
pared with levels measured at baseline. 
The percentage of neutrophils and
eosinophils in induced sputum obtained after
formaldehyde exposure was not statistically
different from that obtained after air-only
exposure. The level of all the parameters mea-
sured in sputum supernatant obtained after
formaldehyde exposure was not significantly
different from that obtained after air-only
exposure (Table 3). 
During the 2 weeks after each exposure,
subjective symptoms and peak flow meas-
urements did not differ signiﬁcantly between
subjects who were exposed to air-only and
those who were exposed to formaldehyde.
Discussion 
Several epidemiologic studies (Franklin et al.
2000; Garrett et al. 1999; Rumchev et al.
2002; Wieslander et al. 1997) have suggested
possible associations between formaldehyde
exposure and either asthma or allergic sensiti-
zation to common aero allergens. These cross-
sectional studies assessed chronic exposure to
low levels of formaldehyde. Concerning the
effect of acute exposures to formaldehyde on
allergic response, the only data available were
reported in a murine model (Sadakane et al.
2002). Several studies have been performed
with air pollutants to assess interaction with
allergenic response; some have shown that
asthmatic response could be enhanced by a
brief preexposure to air pollutants, in particu-
lar, nitrogen dioxide or ozone (Barck et al.
2005; Jörres et al. 1996; Molﬁno et al. 1991;
Strand et al. 1997; Tunnicliffe et al. 1994). 
The hypothesis that a brief exposure to
ambient levels of formaldehyde enhances asth-
matic response to allergen has not yet been
reported in controlled human exposure studies.
The aim of this study was to examine whether
a 1-hr exposure to 500 μg/m3 formaldehyde
enhances the asthmatic response to inhaled
pollen allergen in subjects with intermittent
asthma. We chose this level of formaldehyde
to remain within realistic conditions while
Ezratty et al.
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Table 2. Results [median (range)] of allergen bronchial challenge performed immediately after exposure to
formaldehyde or air-only and methacholine bronchial challenge performed 8 hr after exposure.
Exposure
Formaldehyde Air-only p-Value
Allergen challenge (PD15FEV1) 0.80 (0.15–2.0) 0.25 (0.10–2.0) 0.06
Methacholine challenge (PD20) 0.23 (0.01–3.6) 0.17 (0.03–4) 0.42
p-Values were determined by signed rank test.
Figure 1. Ratios between PD15FEV1 and PD20 metha-
choline measurements for each subject (after
formaldehyde exposure divided by after air-only
exposure). The ratios between the PD15FEV1 mea-
surements are always ≥ 1, showing an unchanged
or a decreased allergen responsiveness with
formaldehyde compared with air-only. The ratios
between the PD20 methacholine measurements
after exposure to formaldehyde and air-only range
from 0.15 to 16.
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with formaldehydemaximizing our chances to demonstrate an
adverse effect. Mean indoor formaldehyde con-
centrations are usually < 500 μg/m3, although
such a concentration can be found in indoor
environments (Institute for Environment and
Health 1996). 
Formaldehyde exposure alone did not
cause any change in lung function, which is in
accordance with earlier reports that concluded
that lung function of healthy nonsmokers and
asthmatics was generally unaffected by expo-
sure to formaldehyde at levels ≤ 3,700 μg/m3
(Sauder et al. 1987).
We found no significant differences
between the bronchial allergen responses after
formaldehyde exposure compared with expo-
sure to air-only. However, there was a ten-
dency toward a lower immediate bronchial
allergen response after exposure to formalde-
hyde compared with air-only, contrary to
expectations. This result is not compatible with
an adverse effect of formaldehyde on asthmatic
response in the conditions tested and might
suggest a protective effect. Such an effect was
reported in mice preexposed to low concentra-
tions of nitrogen dioxide (Hubbard et al. 2002;
Proust et al. 2002). Moreover, Fujimaki et al.
(2004) showed a decreased production of
IL-1β in ovalbumin in immunized mice after
exposure to a low dose of formaldehyde.
We assessed the effect of formaldehyde
using conditions that minimize the possibility
of bias: the order of exposures to formaldehyde
or puriﬁed air was both randomized and dou-
ble blinded. Subjects were tested in the same
controlled conditions and with a constant level
of air pollutants, temperature, and humidity.
The delay between exposures was consistent
with the literature concerning this type of
study (Strand et al. 1997). The longer the
wash-out period, the higher the risk of devel-
oping respiratory infections; we considered
2 weeks a good compromise between the risk
of bias because of a late reaction after the aller-
gen challenge and the risk of exclusion because
of infection. Furthermore, if the delay between
exposures had had an effect, we would have
found different results between the ﬁrst expo-
sure to formaldehyde or air-only (no wash-out)
and the second exposure to formaldehyde or
air, which was not the case (i.e., no “order
effect”). 
Post hoc calculations showed that the
power of the study was sufﬁcient (> 80%) to
show a significant difference if there was a
2-fold variation in PD15FEV1 between the two
arms. We observed an increase in PD15FEV1
after formaldehyde exposure compared with
air-only exposure (Figure 1). The increase was
near statistical significance (two-sided,
p = 0.06). The true value of the variation in
PD15FEV1 may correspond to a decreased
responsiveness with formaldehyde compared
with air-only or to no change. However, in
spite of the low number of patients, the
power of the study is sufficient to conclude
that the probability for an increased respon-
siveness with formaldehyde is very low (3%).
Moreover, if there was an increased respon-
siveness, the increase would probably be so
small that it would be impossible to demon-
strate, even with a very large study. 
Corren (1992) showed that a late bronchial
response occurs 2 to > 12 hr after allergen
exposure. In the present study, methacholine
challenge and induced sputum tests were per-
formed 8 hr after the end of allergen
bronchial challenge, approximately when the
maximum airway inflammatory reaction to
allergen occurs. We observed no significant
modification in airway responsiveness to
methacholine after formaldehyde exposure at
this time (8 hr after exposure). To assess air-
way inﬂammation, bronchial biopsy remains
the gold standard. However, this process is
invasive compared with induced sputum,
which has proven to be a reproducible, sensi-
tive, and valid method for the assessment of air-
way inflammation (Wilson 2002). Induced
sputum has been used to detect cytokines in
patients with bronchial asthma, and the
up-regulation of cytokines in the airways can be
assessed using noninvasive techniques, includ-
ing sputum induction (Taha et al. 2001). In the
present study, we measured in induced sputum
several inﬂammatory cytokines and mediators
that are well-known to be involved in the
physiopathology of asthma. Formaldehyde
exposure did not signiﬁcantly affect inﬂamma-
tory cytokines and mediators measured in spu-
tum 8 hr after the end of the bronchial allergen
challenge. However, the total dose of allergen
required to reach the expected respiratory effect
was higher after formaldehyde exposure than
after air-only exposure (0.8 IR vs. 0.25 IR). A
potential effect of formaldehyde on the
response to methacholine challenge could have
been masked because of the differences in aller-
gen exposure between the two arms. It also
applies for the airway inﬂammatory response. 
Our study included patients with intermit-
tent asthma who were not taking any anti-
inﬂammatory therapy; although we observed
no effect in this particular group of patients,
this does not necessarily mean that the results
can be generalized to patients with more severe
asthma. Therefore, additional research is
needed to examine effects among individuals
with severe asthma.
To our knowledge, this is the first con-
trolled human study examining possible inter-
actions between formaldehyde exposure and
allergen on asthmatic response. In this study,
exposure to 500 μg/m3 formaldehyde did not
enhance the asthmatic response to allergen. We
even observed a trend to a protective effect.
Future studies assessing effects of formaldehyde
at higher doses, or with repeated or longer
exposures, are needed to clarify interactions
between formaldehyde and allergens in airways
of patients with asthma.
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Table 3. Results [median (range)] for parameters measured in sputum.
Exposure
Baseline Formaldehyde Air-only p-Valuea
Total no. of cells 244 (213–496) 255 (215–633) 258 (229–438) 0.50
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ECP (ng/mL)b 57 (3.8–130) 130 (3.9–200) 105.5 (41–200) 0.92
Eotaxin (pg/mL) 0 (0–0) 0 (0–14) 0 (0–15) 1.00
GM-CSF (pg/mL) 0 (0–1.6) 0 (0–0.69) 0 (0–7.87) 0.12
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TNF-α (pg/mL) 0.26 (0–3.4) 0.16 (0–1.3) 0.26 (0–3.6) 0.20
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